Compare Sana Biotechnology Inc (SANA) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard S&P 500 ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Vanguard S&P 500 ETF trades at $710.76. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VOO | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $5.92 | $710.71 |
52-Week Low | $2.68 | $580.93 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
VOO trades at $710.69 with minimal daily movement (+0.01%), maintaining a bullish technical stance as the S&P 500 ETF approaches record highs. The overall technical signal is bullish with strong moving average support, though oscillators show neutral momentum. Recent news highlights the S&P 500's elevated valuation levels while institutional interest remains strong, with Bay Colony Advisory increasing its position by 8.6% in Q2 2026.
The ETF's outlook remains positive given its core exposure to large-cap US equities, but investors face valuation concerns with the S&P 500 trading at historically high multiples. Key risks include market volatility around inflation data and potential profit-taking near resistance levels, while institutional accumulation suggests continued confidence in the broader market trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
